questionText: To ask the Secretary of State for Health and Social Care, whether his Department has an estimate of the earliest possible date Jascayd (nerandomilast) could be available to idiopathic pulmonary fibrosis patients.
answerText: Nerandomilast does not currently have a United Kingdom marketing authorisation for use in the treatment of idiopathic pulmonary fibrosis. It is currently being evaluated by the National Institute for Health and Care Excellence (NICE) which makes recommend...
heading: Idiopathic Pulmonary Fibrosis: Drugs